Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells

Tumor Biology

Volumn 34, Issue 3, 2013, Pages 1887-1894

  Zhang, Guojun ^a   Zhang, Zhe ^a   Liu, Zhuogang ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Clinical stage; Histopathological grade; Polo like kinase 1; Renal carcinoma; Scytonemin

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; POLO LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE INHIBITOR; SCYTONEMIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; COLONY FORMATION; ENZYME ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRANSITIONAL CELL CARCINOMA; TUMOR INVASION; WESTERN BLOTTING;

EID: 84878693926     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0732-0     Document Type: Article

References (23)

1. Kyttaris VC. Kinase inhibitors: a new class of antirheumatic drugs. Drug Des Devel Ther. 2012;6:245-50.
2. Kuroda N, Shiotsu T, Hes O, Michal M, Shuin T, Lee GH. Acquired cystic disease-associated renal cell carcinoma with gain of chromosomes 3, 7, and 16, gain of chromosome X, and loss of chromosome Y. Med Mol Morphol. 2010;43(4):231-4.
3. Luo J, Liu X. Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development. Protein Cell. 2012;3(3):182-97.
4. Sakai D, Dixon J, Dixon MJ, Trainor PA. Mammalian neurogenesis requires Treacle-Plk1 for precise control of spindle orientation, mitotic progression, and maintenance of neural progenitor cells. PLoS Genet. 2012;8(3):e1002566.
5. Kachaner D, Filipe J, Laplantine E, et al. Plk1-dependent phosphorylation of optineurin provides a negative feedback mechanism for mitotic progression. Mol Cell. 2012;45(4):553-66.
6. Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Menendez JA. Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus. Cell Cycle. 2011;10(8):1295-302.
7. Yoon HE, Kim SA, Choi HS, Ahn MY, Yoon JH, Ahn SG. Inhibition of Plk1 and Pin1 by 5′-nitro-indirubinoxime suppresses human lung cancer cells. Cancer Lett. 2012;316(1):97-104.
8. Francescangeli F, Patrizii M, Signore M, et al. Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells. Stem Cells. 2012;30(9):1819-30.
9. Peng DX, Luo M, Qiu LW, He YL, Wang XF. Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer. Oncol Rep. 2012;27(4):1238-44.
10. de Oliveira JC, Brassesco MS, Pezuk JA, et al. In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells. J Drugs Dermatol. 2012;11(5):587-92.
11. Maire V, Némati F, Richardson M, et al. Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer. Cancer Res. 2013;73(2):813-23.
12. Zhang Y, Du XL, Wang CJ, et al. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells. Gastroenterology. 2012;142(3):521-30.e3.
13. Zhang Z, Zhang G, Kong C. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder. Urol Oncol. 2011 Dec 20, [Epub ahead of print].
14. Deeraksa A, Pan J, Sha Y, et al. Plk1 is upregulated in androgen-insensitive prostate cancer cells and its inhibition leads to necroptosis. Oncogene. 2012 Aug 13, [Epub ahead of print].
15. Lee C, Fotovati A, Triscott J, et al. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice. Stem Cells. 2012;30(6):1064-75.
16. Pellegrino R, Calvisi DF, et al. Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma. Hepatology. 2010;51(3):857-68.
17. Medema RH, Lin CC, Yang JC. Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC. Clin Cancer Res. 2011;17(20):6459-66.
18. Golsteyn RM, Schultz SJ, Bartek J, Ziemiecki A, Ried T, Nigg EA. Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. J Cell Sci. 1994;107(Pt 6):1509-17.
19. Kettenbach AN, Schweppe DK, Faherty BK, Pechenick D, Pletnev AA, Gerber SA. Quantitative phosphoproteomics identifies substrates and functional modules of Aurora and Polo-like kinase activities in mitotic cells. Sci Signal. 2011;4(179):rs5.
20. Lobjois V, Froment C, Braud E, et al. Study of the docking-dependent PLK1 phosphorylation of the CDC25B phosphatase. Biochem Biophys Res Commun. 2011;410(1):87-90.
21. Smits VA, Klompmaker R, Arnaud L, Rijksen G, Nigg EA, Medema RH. Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol. 2000;2(9):672-6.
22. Zhang Z, Su WH, Feng C, et al. Polo-like kinase 1 may regulate G2/M transition of mouse fertilized eggs by means of inhibiting the phosphorylation of Tyr 15 of Cdc2. Mol Reprod Dev. 2007;74(10):1247-54.
23. McInnes C, Mezna M, Fischer PM. Progress in the discovery of polo-like kinase inhibitors. Curr Top Med Chem. 2005;5(2):181-97.